Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income (loss)	$ (20,129,284)	$ (22,414,640)	$ (5,229,725)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	376,213	479,595	512,366
Amortization	94,995		13,147
Unrealized currency loss on short-term investments		52,726
(Gain) loss on equipment disposal	(3,222)	18,997
Impairment loss on property and equipment	293,162
Noncash compensation	1,473,449	2,535,217	4,044,858
Warrant issuance costs		244,857	150,827
Change in value of warrant liability	(2,864,348)	(7,701,981)	(19,821,787)
Patent costs			1,481,318
Changes in operating assets and liabilities:
Accounts receivable	(416,495)	1,736,199	3,641,491
Other current assets	697,966	(182,428)	123,197
Other long-term assets	(29,732)	(6,414)	(919)
Accounts payable	(713,502)	609,522	(348,282)
Deferred revenue	(2,062,332)	3,238,124	(2,317,218)
Accrued expenses	180,483	740,723	845,337
Net cash used in operating activities	(23,102,647)	(20,649,503)	(16,905,390)
Cash flows from investing activities:
Purchase of short-term investments		(5,220,781)	(5,520,000)
Sale of short-term investments	2,197,940	8,312,120	434,835
Purchase of equipment	(139,491)	(178,271)	(655,553)
Increase in restricted cash	(1,497,740)	(1,541,366)
Investment in patents			(326,171)
Net cash provided by (used in) investing activities	560,709	1,371,702	(6,066,889)
Cash flows from financing activities:
Issuance of common stock, net of offering costs		15,675,727	21,946,801
Net proceeds from issuance of debt	7,327,675
Exercise of options	12,392	2,375	532,408
Repayment of capital lease obligation	(78,125)	(52,410)
Exercise of warrants			949,793
Net cash provided by financing activities	7,261,942	21,519,249	34,769,442
Effect of exchange rate change on cash and cash equivalents	(323,621)	538,046	156,889
Increase (decrease) in cash and cash equivalents	(15,603,617)	2,779,494	11,954,052
Cash and cash equivalents at beginning of period	25,652,083	22,872,589	10,918,537
Cash and cash equivalents at end of period	10,048,466	25,652,083	22,872,589
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	128,811	23,708
Supplemental schedule of noncash financing activities:
Fair value of warrants issued in connection with debt	117,999
Equipment acquired through lease financing		221,690
Conversion of warrant liability to equity upon warrant exercise			995,428
Noncash financing costs on common stock offering			207,905
Noncash warrant issuance costs			19,361
Incuron, LLC [Member]
Cash flows from financing activities:
Noncontrolling interest capital contribution		5,893,557	2,340,374
Panacela [Member]
Cash flows from financing activities:
Noncontrolling interest capital contribution			$ 9,000,066